Veradermics

#Dermatology #Hair Loss #Androgenetic Alopecia

New Haven, CT-based dermatology biotech developing dissolvable microarray patches for pattern hair loss (androgenetic alopecia), with a clinical-stage lead candidate.

Company Info

Sector:Dermatology

Headquarters:New Haven, CT, USA

Founded:2018

Website:www.veradermics.com/

Upcoming Milestones & Key Dates

2026-Q3

IPO

IPO follow-on offering expected

2026-Q4

clinical

Phase 2 VER-001 topline data read-out

Clinical Development Pipeline

VER-001 microarray patch

Target: Topical minoxidil via dissolvable microneedle

Pattern hair loss (androgenetic alopecia)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

VER-002

Target: Dermatology

Alopecia areata

Preclinical

Phase 1

Phase 2

Phase 3

Approved

VER-003

Target: TBD

Other dermatology indications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom ↗

Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom (reported by BioSpace)

Leadership Team

Reid Waldman

Founder and Chief Executive Officer

Careers & Job Openings

See all open roles

All departments

See company careers site

Apply Now →